Zymeworks Announces Participation in Upcoming Investor Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Zymeworks (ZYME) PT Raised to $26 at Leerink Partners
November 21, 2024 9:22 AM ESTLeerink Partners analyst Andrew Berens raised the price target on Zymeworks (NASDAQ: ZYME) to $26.00 (from $25.00) while maintaining a Outperform rating.
The analyst comments " Bottom Line: The FDA granted accelerated approval to Ziihera (zanidatamab) in pre-treated HER2+ (IHC3+) biliary tract cancer (BTC) patients ahead of its PDUFA date of Nov. 29, 2024. This approval was widely anticipated. As a reminder, ZYME previously outlicensed Ziihera to partner Jazz Pharmaceuticals (JAZZ, Goodman, OP) in 2022 and will now receive a $25mn regulatory milestone from JAZZ. ZYME remains eligible... More
